These data were confirmed in another study in which we validated our flow-cytometry method in a larger series and documented the presence of CD26+ LSCs in PB samples of all 211 newly diagnosed CML patients tested. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.